Adaptimmune Therapeutics earnings date
Want to see ADAPY full AI Analyst Report?
Adaptimmune Therapeutics (ADAPY) Q1 2025 Earnings Report
ADAPY Q1 2025 EPS Results
- Actual EPS
- -$0.03
- Consensus EPS
- -$0.09
- Beat/Miss
- Beat by +$0.06
- One Year Ago EPS
- -$0.03
ADAPY Q1 2025 Revenue Results
- Actual Revenue
- $7.31M
- Expected Revenue
- $7.06M
- Beat/Miss
- Beat by +$253.97K
- YoY Revenue Growth
- +28.87%
Earnings Announcement Details
- Quarter
- Q1 2025
- Date
- 05/13/2025
- Time
- Before Open
- Conference Call
- Tuesday, May 13, 2025
Q1 2025 Earnings Call Audio
Q1 2025 Earnings Slide Deck
No slide deck is available for this earnings event.
Q1 2025 Earnings Call Summary
Adaptimmune reported a very successful launch of TECELRA with strong initial sales and effective patient access. The early activation of treatment centers and manufacturing success further support their positive outlook. However, financial challenges remain with doubts about their ability to continue as a going concern.
In the first quarter of 2025, Adaptimmune reported significant progress in the launch of TECELRA, with 21 patients apheresed to date, including 13 in Q1 and 8 in early Q2. The company provided revenue guidance for the full year, anticipating TECELRA sales of $35 million to $45 million. Adaptimmune reported invoicing 14 TECELRA treatments in 2025, including 6 in Q1, resulting in $4 million in net sales, and 8 additional invoiced treatments early in Q2. The company achieved 100% manufacturing success, with an average turnaround from apheresis to lot release of 27 days, surpassing the 30-day target. Adaptimmune's network includes 28 active treatment centers, with expectations to reach 30 by year-end, a year ahead of schedule. No patient access issues have been reported, with no denials to date. Adaptimmune foresees peak sales of $400 million from its TECELRA and lete-cel sarcoma franchise, with lete-cel launch activities underway, targeting a 2026 approval.
- Strong TECELRA Launch with Revenue GuidanceAdaptimmune reported a successful launch of TECELRA with 21 patients apheresed in 2025, 13 in Q1 and 8 in early Q2. They provided revenue guidance for the full year of $35 million to $45 million in TECELRA sales.
- Early Activation of Treatment CentersAdaptimmune has 28 treatment centers accepting referrals and expects to have a full network of 30 centers by the end of 2025, a year earlier than expected.
- 100% Manufacturing SuccessThe TECELRA manufacturing center in Philadelphia reported 100% success with all doses released meeting specifications, and an average turnaround time of 27 days, beating the target of 30 days.
- No Patient DenialsEffective patient access to TECELRA with no patient denials reported to date.
- Future Growth with lete-celAnticipation of lete-cel approval in 2026, which could more than double the addressable patient market within the sarcoma franchise.
ADAPY Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Aug 12, 2026 | 2026 (Q2) | ―- | -0.12 | ― | |
| May 20, 2026 | 2026 (Q1) | -0.03- | -0.03 | ― | |
| Mar 10, 2026 | 2025 (Q4) | -0.06-0.03 | -0.05 | 40.00% (+0.02) | |
| Nov 05, 2025 | 2025 (Q3) | -0.12- | -0.01 | ― | |
| Aug 13, 2025 | 2025 (Q2) | -0.04-0.02 | 0.04 | -150.00% (-0.06) | |
| May 13, 2025 | 2025 (Q1) | -0.09-0.03 | -0.03 | 0.00% (+0.00) | |
| Mar 20, 2025 | 2024 (Q4) | -0.03-0.05 | -0.04 | -25.00% (-0.01) | |
| Nov 13, 2024 | 2024 (Q3) | -0.01-0.01 | -0.03 | 66.67% (+0.02) | |
| Aug 12, 2024 | 2024 (Q2) | -0.040.04 | -0.02 | 300.00% (+0.06) | |
| May 15, 2024 | 2024 (Q1) | -0.15-0.03 | 0 | ― |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

